Abstract
It is estimated that almost 70% of patients affected by multiple sclerosis (MS) suffer from urinary symptoms, with devastant impact on Quality of Life (QoL). The major aims of management should be to ameliorate the patients quality of life and to prevent the frequent complications of bladder dysfunction such as infention and renal damage. Therapy can usually eliminate or reduce the symptoms of neuropathic bladder. In the following pages is discussed the complex management of urinary symptoms in MS patients.
MeSH terms
-
Antidepressive Agents, Tricyclic / administration & dosage
-
Antidepressive Agents, Tricyclic / therapeutic use
-
Benzhydryl Compounds / administration & dosage
-
Benzhydryl Compounds / therapeutic use
-
Botulinum Toxins / administration & dosage
-
Capsaicin / administration & dosage
-
Capsaicin / therapeutic use
-
Cresols / administration & dosage
-
Cresols / therapeutic use
-
Diterpenes / administration & dosage
-
Diterpenes / therapeutic use
-
Electric Stimulation Therapy
-
Humans
-
Multiple Sclerosis / complications*
-
Multiple Sclerosis / physiopathology
-
Muscarinic Antagonists / administration & dosage
-
Muscarinic Antagonists / therapeutic use
-
Phenylpropanolamine*
-
Prognosis
-
Quality of Life
-
Time Factors
-
Tolterodine Tartrate
-
Urinary Bladder, Neurogenic / diagnosis
-
Urinary Bladder, Neurogenic / drug therapy
-
Urinary Bladder, Neurogenic / physiopathology
-
Urinary Bladder, Neurogenic / rehabilitation
-
Urinary Bladder, Neurogenic / surgery
-
Urinary Bladder, Neurogenic / therapy*
-
Urodynamics
Substances
-
Antidepressive Agents, Tricyclic
-
Benzhydryl Compounds
-
Cresols
-
Diterpenes
-
Muscarinic Antagonists
-
Phenylpropanolamine
-
Tolterodine Tartrate
-
resiniferatoxin
-
Botulinum Toxins
-
Capsaicin